非转移性前列腺癌根治术后发生第二原发癌的危险因素分析

doi:10.3969/j.issn.1006-7795.2023.03.012

首都医科大学学报 ›› 2023, Vol. 44 ›› Issue (3): 433-438.doi: 10.3969/j.issn.1006-7795.2023.03.012

• 泌尿生殖系统肿瘤临床研究 • 上一篇下一篇

非转移性前列腺癌根治术后发生第二原发癌的危险因素分析

朱光艺¹，王润锦²，熊天宇²，叶小波²，刘占良¹，曹放²，林哲闽¹，牛亦农^1*

1.首都医科大学附属北京世纪坛医院泌尿外科，北京 100038；2.首都医科大学附属北京朝阳医院泌尿外科，北京 100020

收稿日期:2023-02-14 出版日期:2023-06-21 发布日期:2023-06-08
通讯作者: 牛亦农 E-mail: niuyinong@mail.ccmu.edu.cn
基金资助:
国家自然科学基金项目（82170783）

Analysis of risk factors for second primary malignancies after radical prostatectomy for non-metastatic prostate cancer

Zhu Guangyi¹, Wang Runjin², Xiong Tianyu², Ye Xiaobo², Liu Zhanliang¹, Cao Fang², Lin Zhemin¹, Niu Yinong^1*

1.Department of Urology, Beijing Shijitan Hospital, Capital Medical University,Beijing 100038，China; 2.Department of Urology, Beijing Chaoyang Hospital,Capital Medical University, Beijing 100020，China

Received:2023-02-14 Online:2023-06-21 Published:2023-06-08
Supported by:
This study was supported by National Natural Science Foundation of China(82170783).

摘要/Abstract

摘要： 目的探索非转移性前列腺癌根治术后发生第二原发癌（secondary primary malignancies，SPM)的危险因素。方法从监测、流行病学和最终结果(Surveillance, Epidemiology, and End Results， SEER)数据库筛选2010年－2015年诊断为T1-4N0M0的前列腺癌患者的临床资料。根据治疗方式分为单纯手术组、手术加放射治疗（以下简称放疗）组和手术加化学药物治疗（以下简称化疗）组，比较不同治疗方式下SPM的发生率及常见部位。结果本研究共纳入患者243 094例，发生SPM者 193 44例（8.0%），发生SPM的中位时间为36个月。发生SPM最常见的前五个部位分别为肺和支气管、膀胱、皮肤、肾和肾盂、结直肠。Logistic回归分析显示，种族、年龄、化疗、放疗为SPM的独立影响因素。手术加化疗组SPM发生率（19.7%）显著高于单纯手术组（6.4%）和手术加放疗组（8.3%)，差异有统计学意义，但3组SPM累及的系统差异无统计学意义，前四位均为消化系统、泌尿系统、免疫系统和呼吸系统。结论前列腺癌患者行手术加放疗和化疗的情况下，SPM发生率增加，尤其是手术加化疗组；不同治疗方案中SPM主要发生部位类似，放疗患者的SPM更容易出现在消化系统。对前列腺癌患者采用不同治疗方式后，除了警惕前列腺癌复发和转移外，还应关注SPM的发生。

关键词: 前列腺癌, 第二原发癌, 发病率, SEER数据库

Abstract: Objective To investigate the risk factors for secondary primary malignancies (SPM) after radical prostatectomy of non-metastatic prostate cancer. Methods The clinical data of patients diagnosed with T1－4N0M0 prostate cancer from 2010 to 2015 were screened from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were divided into operation group, operation plus radiotherapy group, and operation plus chemotherapy group according to the treatment methods. The incidence and common sites of SPM under different treatment methods were compared. Results A total of 243 094 patients were included in this study, and 19 344 patients (8.0%) developed SPM. The median time for SPM was 36 months.The top five most common organs of SPM were lungs and bronchus, bladder, skin, kidney and renal pelvis, and colorectal. Logistic regression analysis showed that race, age, chemotherapy and radiotherapy were independent factors influencing SPM. The incidence of SPM in the surgery plus chemotherapy group (19.7%) was significantly higher than that in operation group (6.4%) and operation plus radiotherapy group (8.3%) (P<0.05), but no significant difference of SPM involved system among three group. The mainly four involved systems were digestive system, urinary system, immune system and respiratory system. Conclusion The incidence of SPM is increased in patients receiving surgery plus radiotherapy or surgery plus chemotherapy, especially in the latter group.The SPM distributed at similar sites, but more likely occurred in the digestive system in patients receiving surgery plus radiotherapy. For prostate cancer patients with different treatment methods, attention should be paid to the occurrence of SPM in addition to the vigilance of recurrence and metastasis of prostate cancer.

Key words: prostate cancer, secondary primary malignancies, incidence of disease, SEER database

中图分类号:

R737.25

朱光艺, 王润锦, 熊天宇, 叶小波, 刘占良, 曹放, 林哲闽, 牛亦农. 非转移性前列腺癌根治术后发生第二原发癌的危险因素分析[J]. 首都医科大学学报, 2023, 44(3): 433-438.

Zhu Guangyi, Wang Runjin, Xiong Tianyu, Ye Xiaobo, Liu Zhanliang, Cao Fang, Lin Zhemin, Niu Yinong. Analysis of risk factors for second primary malignancies after radical prostatectomy for non-metastatic prostate cancer[J]. Journal of Capital Medical University, 2023, 44(3): 433-438.

参考文献

［1］Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209－249.
［2］Welch H G, Albertsen P C. Reconsidering prostate cancer mortality—the future of PSA screening［J］. N Engl J Med, 2020, 382(16): 1557－1563.
［3］Teo M Y, Rathkopf D E, Kantoff P. Treatment of advanced prostate cancer［J］. Annu Rev Med, 2019, 70: 479－499.
［4］DeSantis C E, Lin C C, Mariotto A B, et al. Cancer treatment and survivorship statistics, 2014［J］. CA Cancer J Clin, 2014, 64(4): 252－271.
［5］Vogt A, Schmid S, Heinimann K, et al. Multiple primary tumours: challenges and approaches, a review［J］. ESMO Open, 2017, 2(2): e000172.
［6］Moertel C G, Dockerty M B, Baggenstoss A H. Multiple primary malignant neoplasms. Ⅰ. Introduction and presentation of data［J］. Cancer, 1961, 14: 221－230.
［7］Fan C Y, Huang W Y, Lin C S, et al. Risk of second primary malignancies among patients with prostate cancer: a population-based cohort study［J］. PLoS One, 2017, 12(4): e0175217.
［8］Van Hemelrijck M, Feller A, Garmo H, et al. Incidence of second malignancies for prostate cancer［J］. PLoS One, 2014, 9(7): e102596.
［9］Schaapveld M, Aleman B M P, Van Eggermond A M, et al. Second cancer risk up to 40 years after treatment for Hodgkins lymphoma［J］. N Engl J Med, 2015, 373(26): 2499－2511.
［10］Chattopadhyay S, Zheng G Q, Hemminki O, et al. Prostate cancer survivors: risk and mortality in second primary cancers［J］. Cancer Med, 2018, 7(11): 5752－5759.
［11］赫捷, 陈万青, 李霓, 等. 中国前列腺癌筛查与早诊早治指南(2022, 北京)［J］. 中华肿瘤杂志, 2022, 44(1): 29－53.
［12］Liu Y, Zhang P P, Zhang Y H, et al. Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study［J］. Sci Rep, 2021, 11(1): 1293.
［13］Bagshaw H P, Arnow K D, Trickey A W, et al. Assessment of second primary cancer risk among men receiving primary radiotherapy vs surgery for the treatment of prostate cancer［J］. JAMA Netw Open, 2022, 5(7): e2223025.
［14］Murray L, Henry A, Hoskin P, et al. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique［J］. Radiother Oncol, 2014, 110(2): 213－228.
［15］Dee E C, Muralidhar V, King M T, et al. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques［J］. Radiother Oncol, 2021, 161: 241－250.
［16］Murray L, Henry A, Hoskin P, et al. Second primary cancers after radiation for prostate cancer: a review of data from planning studies［J］. Radiat Oncol, 2013, 8: 172.
［17］Jahrei M C, Heemsbergen W D, Van Santvoort B, et al. Impact of advanced radiotherapy on second primary cancer risk in prostate cancer survivors: a nationwide cohort study［J］. Front Oncol, 2021, 11: 771956.
［18］Buwenge M, Scirocco E, Deodato F, et al. Radiotherapy of prostate cancer: impact of treatment characteristics on the incidence of second tumors［J］. BMC Cancer, 2020, 20(1): 90.
［19］Jahrei M C, Aben K K H, Hoogeman M S, et al. The risk of second primary cancers in prostate cancer survivors treated in the modern radiotherapy era［J］. Front Oncol, 2020, 10: 605119.
［20］Wallis C J D, Mahar A L, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis［J］. BMJ, 2016, 352: i851.
［21］Wood M E, Vogel V, Ng A, et al. Second malignant neoplasms: assessment and strategies for risk reduction［J］. J Clin Oncol, 2012, 30(30): 3734－3745.
［22］Travis L B, Wahnefried W D, Allan J M, et al. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors［J］. Nat Rev Clin Oncol, 2013, 10(5): 289－301.
［23］Mehtl J, Zong J H, Vassilev Z, et al. Overall survival and second primary malignancies in men with metastatic prostate cancer［J］. PLoS One, 2020, 15(2): e0227552.
［24］Preisser F, Mazzone E, Knipper S, et al. Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy［J］. Can Urol Assoc J, 2020, 14(5): E173-E179.
［25］孙俊杰, 李双庆. 多原发癌病因及发病机制的探索［J］. 中国全科医学, 2017, 20(9): 1136－1141.

[1]	刘畅, 郭默宁, 袁颖超, 郑建鹏, 杨金奎. 2013至2018年北京地区1型糖尿病发病率性别差异及预测[J]. 首都医科大学学报, 2023, 44(3): 370-374.
[2]	熊天宇, 牛亦农. 前列腺周围脂肪组织影响前列腺癌发展的机制[J]. 首都医科大学学报, 2023, 44(3): 457-462.

非转移性前列腺癌根治术后发生第二原发癌的危险因素分析

Analysis of risk factors for second primary malignancies after radical prostatectomy for non-metastatic prostate cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价